s6y

BIOVIE INC.

Ticker
BIVI, BIVIW
CIK
1580149
Industry
Pharmaceutical Preparations
Formerly
NANOANTIBIOTICS, INC.

Financials 61

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-K Annual Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-Q Quarterly Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-K Annual Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-Q Quarterly Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-K Annual Report for period ending Jun 30, 2024

All 61 financials filings

News 97

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 97 news filings

Ownership 159

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 159 ownership filings

Prospectus 82

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  3. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  4. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  5. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  6. S-1/A General form of registration statement for all companies including face-amount certificate companies
  7. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  8. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  9. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  10. S-1/A General form of registration statement for all companies including face-amount certificate companies

All 82 prospectus filings

Proxies 26

  1. DEF 14A Definitive proxy statements
  2. DEF 14A Definitive proxy statements
  3. DEF 14A Definitive proxy statements
  4. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  5. PRE 14C Preliminary information statement not related to a contested matter or merger/acquisition
  6. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  7. DEF 14A Definitive proxy statements
  8. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  9. DEF 14A Definitive proxy statements
  10. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition

All 26 proxies filings

Other 90

  1. D Exempt (Private) Offering
  2. SCHEDULE 13G/A
  3. SCHEDULE 13G
  4. SCHEDULE 13G
  5. SCHEDULE 13G/A
  6. SCHEDULE 13G
  7. EFFECT Notice of Effectiveness
  8. SCHEDULE 13D
  9. EFFECT Notice of Effectiveness
  10. POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing

All 90 other filings